FUNDAMENTALS
EdgeFII/DII
LUPINLupin
₹2,014.00+0.76%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
LUPINNSE · EquityPharmaceuticals

Lupin

ISIN
INE326A01037
Instrument key
NSE_EQ|INE326A01037
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹2,014.00+15.20 · +0.76%
Day rangecircuit ₹1,812.60 – ₹2,215.40
1,985.10
2,014.00

as of 21/11/2026, 5:28:05 pm

Open
₹1,992.00
Day high
₹2,014.00
Day low
₹1,985.10
Prev. close
₹1,998.80
Volume
6.31 L
VWAP
₹1,995.55

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

1 month · 30-minute candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX
Change · 1M
+5.20%
1,914.40 → 2,014.00
Period high
₹2,062.10
4/11/2026
Period low
₹1,892.90
23/10/2026
From high
-2.33%
+6.40% from low
Avg volume
54.1K
1.49 Cr total
Candles
276
134 up / 136 down
20 Nov 2026O 1,998.00H 2,014.00L 1,998.00C 2,014.00Vol 46.3K
SMA 20SMA 50Averages need 50 candles before they begin
Candle data276 rows of open, high, low, close and volumeShowHide
20 Nov 20261,998.002,014.001,998.002,014.00+0.80%16.0046.3K
20 Nov 20261,989.601,999.701,987.101,998.00+0.42%12.601.35 L
20 Nov 20261,992.501,993.201,987.001,989.70-0.14%6.2089.9K
20 Nov 20261,999.501,999.601,989.201,993.00-0.33%10.401.12 L
20 Nov 20262,005.402,010.001,999.601,999.60-0.29%10.4032.1K
20 Nov 20262,003.902,009.002,002.302,005.50+0.08%6.7028.4K
20 Nov 20261,993.602,004.001,992.602,004.00+0.52%11.4022.4K
20 Nov 20261,987.101,995.001,986.701,993.50+0.32%8.309.4K
20 Nov 20261,988.301,994.901,986.001,987.00-0.07%8.9044.9K
20 Nov 20261,990.501,990.501,985.101,988.30-0.11%5.4011.3K

Historical price and volume data · Showing 1–10 of 276

1 / 28

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

17.6
Company
17.6
Sector
-45.02

Worse than sector by 139%

P/B

Price ÷ book value per share

3.82
Company
3.82
Sector
4.21

Better than sector by 9%

ROA

Net income ÷ total assets

13.08%
Company
13.08%
Sector
1.19%

Better than sector by 999%

ROE

Net income ÷ shareholders' equity

21.65%
Company
21.65%
Sector
-0.4%

Better than sector by 5512%

ROCE

EBIT ÷ capital employed

24.54%
Company
24.54%
Sector
15.44%

Better than sector by 59%

Quick Ratio

Liquid assets ÷ current liabilities

1.42
Company
1.42
Sector
4.8

Worse than sector by 70%

EV/EBITDA

Enterprise value ÷ EBITDA

10.24
Company
10.24
Sector
22.86

Better than sector by 55%

04/Business

About the company

Sector: Pharmaceuticals

Lupin Limited is a global pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and operates in the Anti-TB and Cephalosporins segments. Its generic formulations include Filgrastim, Peg filgrastim, Etanercept and Albuterol. Its diabetes brands include Gibtulio, Ajaduo, Gibtulio Met, ONDERO and ONDERO MET. Its other brands include AntaGolin, RyChol and others. Its Huminsulin range of products includes Insulin Human.

Sector market cap (INR)
₹91,916 Cr

reported in crore

Sector market cap (USD)
$10.21B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Standalone income statement

Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Sep 2026
₹3,663 Cr
-49.65% vs Jun 2026
Net profit · Sep 2026
-₹6 Cr
-100.22% vs Jun 2026
Operating margin
0.1%
was 49.6%
Revenue CAGR · 4p
-7.3%
profit — · op -83.1%
Filed order
Revenue3,6637,2745,3234,601
Revenue growthreported-49.6%36.6%15.7%—
Operating profit43,6102,602868
Operating profit growthreported-99.9%38.7%199.8%—
Operating marginderived0.1%49.6%48.9%18.9%
Net profit-62,7152,164717
Net profit growthreported-100.2%25.5%201.6%—
Net marginderived-0.2%37.3%40.6%15.6%
EPS — basic₹/share, annual——139.38—

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue19,51316,96814,66711,259
Other Income940253116210
Total Revenue20,45317,22114,78211,469
Total Expenses13,16512,30711,99710,942
Profit Before Tax7,6944,8372,785527
Tax1,328864459102
Profit After Tax6,3673,9732,326425
EPS - Basic139.3887.1051.109.35
EPS - Diluted139.0186.7950.879.31

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Standalone balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹36,103 Cr
+26.98% YoY
Total liabilities
₹5,969 Cr
Net worth
₹30,134 Cr
Liabilities ÷ assets
16.5%
lower means a lighter balance sheet
Filed order
Total assets36,10328,43224,92322,684
Total liabilities5,9694,1544,3204,272
Net worthderived30,13424,27820,60318,412
Liabilities ÷ assetsderived16.5%14.6%17.3%18.8%
Asset growthderived27.0%14.1%9.9%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets20,50816,53715,63515,113
Current Assets15,59511,8959,2887,571
Total Assets36,10328,43224,92322,684
Current Liabilities4,8323,3003,6943,628
Net Current Asset10,7638,5955,5943,943
Non-Current Liabilities1,137854626644
Equity Capital30,13424,27820,60318,412
Total Equity & Liabilities36,10328,43224,92322,684

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Standalone cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹5,540 Cr
+126.61% YoY
Investing
-₹5,649 Cr
Financing
-₹121 Cr
Free cash flow
-₹109 Cr
operating + investing
Filed order
Operating activities5,5402,4452,5041,794
Operating changereported126.6%-2.4%39.6%—
Investing activities-5,649-1,766-1,599-1,269
Investing changereported-219.8%-10.5%-26.0%—
Financing activities-121-460-867-498
Financing changereported73.7%46.9%-74.0%—
Net cash flowderived-2302183827
Free cash flowoperating + investing-109678905525

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax7,6944,8372,785527
Income before WC changes7,3575,5493,5561,111
Change in Assets-1,344-2,042-1,598529
Change in Liabilities682-254693281
Change in WC-662-2,296-905810
Cash flow from Operations5,5402,4452,5041,794
Cash flow from Investing-5,649-1,766-1,599-1,269
Cash flow from Financing-121-460-867-498
Total Cash Flow-2302183827
Cash (Start of the year)3421248659
Cash (End of the year)11234212486

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
46.85%
0.00 pts QoQ
FII
23.28%
+0.86 pts QoQ
DII (other)
9.20%
-0.61 pts QoQ
Mutual funds
14.58%
-0.26 pts QoQ
Retail & others
6.09%
+0.01 pts QoQ
Filed order
Promoters46.9%46.9%46.9%46.9%
FII23.3%22.4%21.7%21.5%
DII (other)9.2%9.8%8.4%7.6%
Mutual funds14.6%14.8%16.9%18.0%
Retail & others6.1%6.1%6.1%6.0%
Promoters — QoQ changepts, derived0.0%-0.0%-0.0%—
FII — QoQ changepts, derived0.9%0.7%0.2%—
DII (other) — QoQ changepts, derived-0.6%1.4%0.8%—
Mutual funds — QoQ changepts, derived-0.3%-2.1%-1.1%—
Retail & others — QoQ changepts, derived0.0%-0.0%0.1%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendFinal₹18.00900.0%17 Jul 202617 Jul 202607 May 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

No news in the last seven days

Company news is available for a rolling one-week window.